Advertisement
Jefferies & Company, Inc. is acting as sole book-running manager in thisoffering.
This offering is being made only by means of a prospectus supplement filedwith the Securities and Exchange Commission (the "SEC") in connection with anautomatic shelf registration statement previously filed by Mindray. Copies ofthe final prospectus supplement and related prospectus, when available, may beobtained from Jefferies & Company, Inc., Attention: Syndicate ProspectusDepartment, 520 Madison Avenue, New York, NY 10022 or at (888) 449-2342 and byvisiting EDGAR on the SEC's website at http://www.sec.gov . This press releaseshall not constitute an offer to sell or the solicitation of an offer to buy,nor shall there be any sale of, these securities in any state or otherjurisdiction in which such offer, solicitation or sale would be unlawful priorto the registration or qualification under the securities laws of any suchstate or jurisdiction. The offering may only be made by means of a prospectus.
Advertisement
About Mindray
Mindray is a leading developer, manufacturer and marketer of medicaldevices worldwide. Mindray maintains global headquarters in Shenzhen, China,U.S. headquarters in Mahwah, New Jersey and multiple sales offices in majorinternational markets. From Mindray's main manufacturing and engineering basein China and through its worldwide distribution network, the Company is ableto supply internationally a broad range of products across three primarybusiness segments, comprised of patient monitoring and life support products,in-vitro diagnostic products and medical imaging systems. For more information,please visit http://ir.mindray.com .
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within themeaning of the safe harbor provisions of the Private Securities LitigationReform Act of 1995. Statements that are not historical facts, includingstatements related to Mindray's public offering of American depositary sharesare forward-looking statements that involve risks and uncertainties. Wordssuch as "believes," "anticipates," "plans," "expects," "intend," "will,""goal," "potential" and similar expressions are intended to identifyforward-looking statements. These forward-looking statements are based uponMindray's current expectations. Actual events and the timing of events coulddiffer materially from those anticipated in such forward-looking statements asa result of these risks and uncertainties, which include, without limitation,risks related to the underwriter's consummation of its obligation to purchasethe securities, whether Mindray will be able to satisfy its conditions toclose the offering and other risks detailed in Mindray's filings with theSecurities and Exchange Commission. You should not place undue reliance onthese forward-looking statements, which speak only as of the date of thispress release. All forward-looking statements are qualified in their entiretyby this cautionary statement, and Mindray undertakes no obligation to reviseor update any forward-looking statements to reflect events or circumstancesafter the date of this press release, except as required by law.For investor and media inquiries please contact: In the U.S.: Evan Smith, CFA FD Tel: +1-212-850-5606 Email: [email protected] John Capodanno FD Tel: +1-212-850-5705 Email: [email protected] In China: May Li Mindray Investor Relations Tel: +86-755-2658-2518 Email: [email protected]
SOURCE Mindray Medical International Limited
